Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation

被引:0
|
作者
Fernandez-Munoz, Hermogenes [1 ,2 ]
Plaza, Eva M. [1 ]
Miguel Rivera-Caravaca, Jose [1 ]
Jose Candela, Maria [1 ]
Romera, Marta [1 ,3 ]
De Arriba, Felipe [1 ]
Lozano, Maria L. [1 ]
Vicente, Vicente [1 ]
Heras, Inmaculada [1 ]
Castilla-Llorente, Cristina [1 ,4 ]
Rivera, Jose [1 ]
机构
[1] Univ Murcia, Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Serv Hematol & Oncol Med,CIBERER,IMIB Arrixaca, Murcia, Spain
[2] Hosp Univ Rafael Mendez, Serv Hematol & Hemoterapia, Lorca, Spain
[3] Hosp Univ Santa Lucia, Serv Hematol & Hemoterapia, Cartagena, Spain
[4] Inst Gustave Roussy, Serv Hematol, Villejuif, France
关键词
Buffy-coat; platelet-rich plasma; correct count increment; platelet transfusion; allogeneic hematopoietic cell transplant; whole blood derived platelets; platelet concentrates; bleeding outcomes; WHOLE-BLOOD; APHERESIS; INCREMENTS; REFRACTORINESS; ENGRAFTMENT; LEUKEMIA; EFFICACY; STORAGE; PLASMA; IMPACT;
D O I
10.1080/10245332.2018.1455434
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Whole blood-derived platelet concentrates can be obtained by the platelet-rich plasma (PRP-PCs) or the buffy-coat (BC-PCs) method. Few studies have shown that BC-PCs display lower in vitro platelet activation, but scarce information exists regarding transfusion efficacy. We have performed a retrospective study assessing platelet transfusion in patients undergoing allogeneic hematopoietic cell transplantation (AHCT) in our clinic, before and after the implementation of BC-PCs. Methods: We reviewed clinical records corresponding to 70 PRP-PCs and 86 BC-PCs prophylactic transfusions, which were performed to 55 AHCT patients. Transfusion efficacy was assessed by the 24-h post-transfusion corrected count increment (24-h CCI) and bleeding events. Clinical factors affecting transfusion outcome were also investigated. Results: Clinical characteristics and the total number of platelet transfusions were similar among groups. Mean donor exposure was 5.8 and 5.0 in each single PRP-PCs and BC-PCs transfusion, respectively (p < 0.01). The 24-h CCI was significantly higher in patients transfused with BC-PCs than in those receiving PRP-PCs (8.3[2.7-13.4] vs. 4.7[1.3-8.1]; p < 0.01). Independent predictors of poor platelet transfusion response included diagnosis other than acute leukemia (HR 8.30; 95% CI 1.96-35.22; p = 0.004), splenomegaly (HR 8.75; 95% CI 2.77-27.60; p < 0.001), graft versus host disease prophylaxis different from cyclosporine A and methotrexate (HR 3.96; 95% CI 1.55-10.14; p = 0.004) and PRP-PCs transfusion (HR 4.54; 95% CI 1.72-12.01; p = 0.002). There were no differences between both groups regarding the bleeding events. Conclusion: In the AHCT setting, we hypothesize that BC-PCs transfusion, when compared to PRP-PCs, results in higher CCI and reduced donor exposure, but provides no significant benefit regarding bleeding outcome.
引用
收藏
页码:712 / 718
页数:7
相关论文
共 48 条
  • [21] Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: Guidelines of the SFGM-TC
    Guillaume, T.
    Porcheron, S.
    Audat, F.
    Bancillon, N.
    Berceanu, A.
    Charbonnier, A.
    Dulery, R.
    Edy, N.
    El Cheikh, J.
    Hermet, E.
    Maurer, N.
    Paul, F.
    Konopacki-Potet, J.
    Turlure, P.
    Wallart, A.
    Boulanger, F.
    Dhedin, N.
    Suarez, F.
    Yakoub-Agha, I.
    PATHOLOGIE BIOLOGIE, 2014, 62 (04): : 193 - 196
  • [22] Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
    Bouchard, Philippe
    Bilodeau, Sarah
    Alain, Karine
    Vadnais, Barbara
    Franco, Martin
    Turgeon, Jacques
    Michaud, Veronique
    THERAPEUTIC DRUG MONITORING, 2016, 38 (03) : 414 - 418
  • [23] Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Liu, Jing
    Zhao, Xiao-Su
    Liu, Yan-Rong
    Xu, Lan-Ping
    Zhang, Xiao-Hui
    Chen, Huan
    Chen, Yu-Hong
    Wang, Feng-Rong
    Han, Wei
    Sun, Yu-Qian
    Yan, Chen-Hua
    Tang, Fei-Fei
    Mo, Xiao-Dong
    Liu, Kai-Yan
    Fan, Qiao-Zhen
    Huang, Xiao-Jun
    Chang, Ying-Jun
    CHINESE MEDICAL JOURNAL, 2018, 131 (23) : 2808 - 2816
  • [24] Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
    Li, Po-Hsien
    Lin, Cheng-Hsien
    Lin, Yu-Hui
    Chen, Tsung-Chih
    Hsu, Chiann-Yi
    Teng, Chieh-Lin Jerry
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [25] Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Nath, Karthik
    Peterson, Kristen
    Brown, Samantha
    Devlin, Sean
    Rodriguez, Natasia
    Barker, Juliet
    Giralt, Sergio
    Gyurkocza, Boglarka
    Jakubowski, Ann
    Papadopoulos, Esperanza
    Ponce, Doris
    Scordo, Michael
    Shah, Gunjan
    Perales, Miguel-Angel
    Sauter, Craig
    Lin, Andrew
    Dahi, Parastoo B.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 81 - 92
  • [26] High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
    Zhang, Gaoqi
    Zhang, Jilei
    Yang, Xinrui
    Zhang, Xinpei
    Yang, Siyuan
    Wang, Jing
    Hu, Kai
    Shi, Jinlong
    Ke, Xiaoyan
    Fu, Lin
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3053 - 3060
  • [27] Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
    Lopez-Sanchez, Cristina
    Valcarcel, David
    Gomez, Valle
    Lopez-Jimenez, Javier
    Serrano, David
    Rubio, Vicente
    Solano, Carlos
    Vazquez, Lourdes
    Ruiz-Camps, Isabel
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2020, 33 (02) : 110 - 115
  • [28] The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
    Sarici, Ahmet
    Erkurt, Mehmet Ali
    Kuku, Irfan
    Kaya, Emin
    Berber, Ilhami
    Bicim, Soykan
    Hidayet, Emine
    Kaya, Ahmet
    Bahcecioglu, Omer Faruk
    Tanriverdi, Lokman Hekim
    Ozkan, Sidika Gulkan
    ISTANBUL MEDICAL JOURNAL, 2023, 24 (02): : 216 - 220
  • [29] eHealth mindfulness-based music therapy for patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized controlled trial protocol
    Fleszar-Pavlovic, Sara E.
    Esquives, Blanca Noriega
    Brito, Arianna E.
    Sia, Ann Marie
    Kauffman, Mary Adelyn
    Lopes, Maria
    Moreno, Patricia I.
    Koru-Sengul, Tulay
    Gong, Rui
    Wang, Trent
    Wieder, Eric D.
    Rueda-Lara, Maria
    Antoni, Michael
    Komanduri, Krishna
    Lesiuk, Teresa
    Penedo, Frank J.
    CONTEMPORARY CLINICAL TRIALS, 2024, 142
  • [30] The assessment of platelet function by thromboelastometry as a point-of-care test to guide Intercept-treated platelet support in hemato-oncological patients and hematopoietic stem cell transplantation recipients
    Leitner, Gerda C.
    Ho, Markus
    Tolios, Alexander
    Hopfinger, Georg
    Rabitsch, Werner
    Wohlfarth, Philipp
    TRANSFUSION, 2020, 60 (07) : 1391 - 1399